Lasa Supergenerics Q1 FY22 Share Price & Earnings Call Analysis
- Market cap
- ₹23 Cr
- ROE
- -19.67%
- Price to sales
- 3.67
- Debt to equity
- 0.20
- 52W high / low
- ₹12.5 / ₹5.06
- Sales growth (5Y)
- -34.03%
- EBITDA margin
- -129.87%
- Net profit margin
- -52.15%
- Promoter holding
- 53.65%
- Sales (last year)
- ₹6 Cr
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
Guidance scorecard · Q1 FY22 call
What Lasa Supergenerics Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ1 FY22 call
20–40%- The company expects a sustainable year-on-year growth of around 20% in sales/revenue.
- There is a plan to launch two blockbuster products with strong and consistent market demand, each with a large market size (one around Rs. 2000 Crores).
- Export contribution has increased significantly to 40%, boosting revenue growth from new geographies like Russia and the Middle East.
- Expansion through new units and debottlenecking existing plants will support volume growth.
- The company emphasizes focusing on core products with low risk profiles rather than diversifying excessively.
- Growth is targeted through backward integration to improve cost efficiency, particularly in Albendazole.
2 more points from Lasa Supergenerics Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY22 call
FlatSee what Lasa Supergenerics Ltd said on margins — free account, 30 seconds.
CapexQ1 FY22 call
Planned- LASA is undertaking capex primarily through internal accruals, maintaining a debt-free status for expansions.
- Capex includes adding new reactors (17-18 procured recently) for new blockbuster products with large market potential (~Rs. 2000 Crores product).
- Expansion involves new unit (Unit II) and debottlenecking existing units; full plant capacity expected to be reached in about one year.
- Backward integration efforts ongoing, especially in Albendazole production to improve cost control and competitiveness.
- Brownfield expansions planned using available land bank (50 acres, with only 5 acres currently used) and environment clearances.
- Focus is on project execution rather than acquiring new companies, aiming high ROI (~10x capex).
2 more points from Lasa Supergenerics Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY22 call
See what Lasa Supergenerics Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY22 call
- The company experienced a decline in topline during Q4 FY2021 due to fewer government tenders as focus shifted to vaccine procurement during the COVID-19 pandemic.
- Recent trends indicate an improvement in demand and growth is expected to cross previous records in the current financial year.
- The export business has seen a phenomenal jump, growing from 17% to 40% of revenues due to new geographic registrations (e.g., Russia).
2 more points from Lasa Supergenerics Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Lasa Supergenerics Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Lasa Supergenerics Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Lasa Supergenerics Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 31.70 | 35.32 | 30.56 | 24.30 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.20 |
| Expenses + | 34.16 | 30.98 | 26.51 | 23.25 | 25.60 | 26.81 | 29.04 | 38.60 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 |
| Operating Profit | -2.46 | 4.34 | 4.05 | 1.05 | 1.06 | -3.99 | 1.80 | 0.79 | 0.27 | 3.41 | -0.50 | -4.00 | -0.75 |
| OPM % | -7.76% | 12.29% | 13.25% | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.50% | -130.72% | -34.09% |
| Other Income + | 0.86 | -18.97 | 0.00 | 0.08 | 0.00 | -8.76 | 0.00 | 1.95 | 8.91 | -21.52 | -20.44 | 0.01 | 0.02 |
| Interest | 0.43 | 0.41 | 0.37 | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 | 0.11 |
| Depreciation | 3.09 | 4.17 | 2.65 | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.80 | 3.90 | 1.57 | 1.57 | 1.57 |
| Profit before tax | -5.12 | -19.21 | 1.03 | -2.11 | -2.06 | -15.97 | -1.86 | -1.31 | 5.91 | -22.12 | -22.54 | -5.68 | -2.41 |
| Tax % | -3.91% | -21.92% | 580.58% | -99.05% | -29.61% | -4.20% | 46.77% | 146.56% | 7.11% | -35.40% | -6.30% | 10.04% | 5.81% |
| Net Profit + | -4.92 | -15.00 | -4.95 | -0.02 | -1.46 | -15.30 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 | -2.55 |
| EPS in Rs | -1.21 | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 | -1.25 | -0.51 |
Financials of Lasa Supergenerics Ltd
Profit & Loss
Annual income statement trend
| Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 64 |
| Expenses + | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 66 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -2 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | -3% | |
| Other Income + | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -42 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 0 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 9 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -53 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| Net Profit + | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -44 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -8.83 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% |
Financials of Lasa Supergenerics Ltd
Balance Sheet
Capital structure and asset base
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| Borrowings + | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 |
| Other Liabilities + | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| Fixed Assets + | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Financials of Lasa Supergenerics Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | -3 |
| Cash from Investing Activity + | 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | -0 | 8 |
| Cash from Financing Activity + | 0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | -2 | -6 |
| Net Cash Flow | 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 | -0 | -0 |
| Free Cash Flow | 0 | -5 | -6 | 29 | 13 | 35 | 12 | -12 | 0 | 5 |
| CFO/OP | -6% | 103% | 397% | 46% | 87% | 73% | 273% | 96% | -45% |
Financials of Lasa Supergenerics Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
Guidance history
How Lasa Supergenerics Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY22 call → | 20–40% | Flat | Planned | — | — |
| Q3 FY21 call → | 0–10% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Lasa Supergenerics Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL